istock-936761078-marrio31

marrio31 / iStockphoto.com

20 November 2018Americas

LSPN Europe 2018: Russian litigation and US second medical use

The strategies of generic makers in Russia have changed dramatically over the past few years, according to Natalia Gulyaeva, partner at Hogan Lovells.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

LSPN Europe 2018: UK has SPC opportunity post-Brexit, says Dentons lawyer

19 November 2018 The UK has an excellent opportunity to adopt laws on supplementary protection certificates that will provide a “clearer” set of legislation post-Brexit, said French lawyer Marianne Schaffner, partner at Dentons.

LSPN Europe 2018: SPCs—important but ‘phenomenally complicated’, say lawyers

16 November 2018 Supplementary protection certificates are hugely important to MSD’s business, according to Elena Böhles, assistant counsel at the pharmaceutical company, based in Hertfordshire, UK.

More on this story

LSPN Europe 2018: UK has SPC opportunity post-Brexit, says Dentons lawyer

19 November 2018 The UK has an excellent opportunity to adopt laws on supplementary protection certificates that will provide a “clearer” set of legislation post-Brexit, said French lawyer Marianne Schaffner, partner at Dentons.

LSPN Europe 2018: SPCs—important but ‘phenomenally complicated’, say lawyers

16 November 2018 Supplementary protection certificates are hugely important to MSD’s business, according to Elena Böhles, assistant counsel at the pharmaceutical company, based in Hertfordshire, UK.

More on this story

LSPN Europe 2018: UK has SPC opportunity post-Brexit, says Dentons lawyer

19 November 2018 The UK has an excellent opportunity to adopt laws on supplementary protection certificates that will provide a “clearer” set of legislation post-Brexit, said French lawyer Marianne Schaffner, partner at Dentons.

LSPN Europe 2018: SPCs—important but ‘phenomenally complicated’, say lawyers

16 November 2018 Supplementary protection certificates are hugely important to MSD’s business, according to Elena Böhles, assistant counsel at the pharmaceutical company, based in Hertfordshire, UK.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent